<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Role Cytosolic Glyceraldehyde-3-Phosphate Dehydrogenase in <br /> Visceral Organ Infection Leishmania donovani <br /> Wen-Wei Zhang, Laura-Isobel McCall, Greg Matlashewski <br /> Department Microbiology Immunology, McGill University, Montreal, Canada <br />  <br /> The initial 7 steps glycolytic pathway glucose 3-phosphoglycerate localized glycosomes Leishmania, <br /> including step 6, catalyzed enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In L. donovani L. mexi- <br /> cana, exists second GAPDH enzyme present cytosol absent L. braziliensis pseudo- <br /> gene L. major. <span id='am-3' about='protege:TO' typeof='owl:Thing'>To</span> investigate role cytosolic GAPDH (cGAPDH), L. donovani cGAPDH-null mutant gener- <br /> ated, conversely, functional L. donovani cGAPDH introduced L. major resulting engineered parasites <br /> were characterized. The L. donovani cGAPDH-null mutant able proliferate rate wild-type parasite in <br /> glucose-deficient medium. However, presence glucose, L. donovani cGAPDH-null mutant consumed glucose <br /> and proliferated slowly wild-type parasite displayed reduced infectivity visceral organs experimentally <br /> infected mice. This demonstrates cGAPDH functional L. donovani required <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-6' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-9' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-11' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-15' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-40' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-47' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-51' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-55' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span>survival</span> visceral organs. Res- <br /> toration cGAPDH activity L. major, contrast, adverse effect L. major proliferation glucose-containing me- <br /> dium, providing possible explanation evolved pseudogene L. major. This study indicates a <br /> difference glucose metabolism L. donovani L. major, represent important factor ability of <br /> L. donovani cause visceral disease. <br />  <br />  <br />  <br /> U     nlike higher eukaryotic cells, glycolytic meta- <br />       bolic process takes place cytosol, protozoan Kineto- <br /> plastida, Trypanosoma Leishmania, glycolytic path- <br />                                                                                       transfer occurred divergence Trypanosoma and <br />                                                                                       Leishmania (24&#226;&#8364;&#8220;26). <br />                                                                                           Considering GAPDH PGK activities detected <br /> way localized mainly specialized organelles called glycosomes                   cytosol T. brucei L. mexicana glycolytic <br /> (1&#226;&#8364;&#8220;8). The enzymes glycolytic pathway Kinetoplastida                    intermediates equilibrate glycosome membranes <br /> glycosomes shown Fig. 1 (4, 5). Glyceraldehyde-3-phosphate                     cytosol, possibly pore-forming channels (27, <br /> dehydrogenase (GAPDH) (EC 1.2.1.12) enzyme catalyzes                      28), glyceraldehyde 3-phosphate derived the <br /> the sixth step glycolysis converting glyceraldehyde 3-phosphate                 active pentose phosphate pathway present cytosol (29, 30), <br /> (GAP) D-glycerate 1,3-bisphosphate (1,3BPGA). Computer                           parallel glycolytic pathway beginning sixth step of <br /> modeling glycolytic flux bloodstream form Trypanosoma brucei                    glycolysis place cytosol trypanosomes and <br /> suggests GAPDH phosphoglycerate kinase (PGK) en-                          Leishmania species expressing cGAPDH (31, 32) (Fig. 1). <br /> zymes partly control glycolytic flux (9&#226;&#8364;&#8220;11). The crystal                   In present study, cGAPDH L. donovani investi- <br /> structures T. brucei, Trypanosoma cruzi, Leishmania mexicana                   gated, including necessary visceral infection. We <br /> glycosomal GAPDHs determined (12&#226;&#8364;&#8220;14). Inhibitors                       investigated effect adding functional cGAPDH <br /> selectively block trypanosome glycosomal GAPDH activity,                      L. major. This study demonstrates cGAPDH <br /> that human GAPDH, shown kill bloodstream T.                           enzyme represents evolutionary difference L. don- <br /> brucei intracellular T. cruzi (10, 15&#226;&#8364;&#8220;17).                                        ovani L. major difference plays role ability <br />     Although Kinetoplastida glycolytic pathway takes place                        L. donovani survive visceral organs. <br /> predominantly glycosomes, GAPDH activity been <br />                                                                                       MATERIALS AND METHODS <br /> detected cytosol T. brucei L. mexicana (18&#226;&#8364;&#8220;20). Two <br />                                                                                       Leishmania strains culture conditions. L. donovani 1S/Cl2D <br /> copies glycosomal GAPDH (gGAPDH) genes tandem array <br />                                                                                       (MHOM/SD/62/1SCl2D) L. major Friedlin V9 strains used in <br /> and copy cytosolic GAPDH (cGAPDH)-encoding gene                            study. Leishmania promastigote culture medium L. donovani <br /> have identified T. brucei L. mexicana (18, 21).                           axenic amastigote culture medium glucose described previ- <br /> gGAPDH- cGAPDH-encoding genes identi-                              ously (33&#226;&#8364;&#8220;36). The RPMI glucose-deficient medium contains 1&#226;&#171;&#187; RPMI <br /> fied Leishmania infantum Leishmania donovani. Interest-                        1640 medium glucose (Sigma R1383), 10% heat-inactivated glu- <br /> ingly, cGAPDH gene evolved pseudogene Leish-                        cose-deficient fetal bovine serum (FBS) (dialyzed 0.15 M NaCl <br /> mania major completely absent Leishmania braziliensis                       10,000-molecular-weight-cutoff cartridge; Sigma F0392), 100- <br /> (22, 23). The gGAPDH enzymes contain sequences glyco- <br /> somal targeting signals. The gGAPDH cGAPDH isoenzymes <br /> share 55% identity amino acid sequence, based                         Received 25 September 2012 Accepted 30 October 2012 <br /> on phylogenetic analysis, proposed genes encod-                       Published ahead print 2 November 2012 <br /> ing gGAPDH cGAPDH isoenzymes independently                                 Address correspondence Greg Matlashewski, greg.matlashewski@mcgill.ca. <br /> acquired trypanosomal ancestor (24). One gene belongs                           Copyright &#194;&#169; 2013, American Society Microbiology. All Rights Reserved. <br /> the trypanosome lineage origin,                           doi:10.1128/EC.00263-12 <br /> entered cell approximately 108 years ago horizontal gene <br />  <br />  <br /> 70   ec.asm.org                                         Eukaryotic Cell   p. 70 &#226;&#8364;&#8220;77                                                 January 2013 Volume 12 Number 1 <br />                                                                                                                                        L. donovani Cytosolic GAPDH <br />  <br />  <br />  <br />                                                                                      TCCTCCCTTCC 5=gacgagatctGCGCAGACAAGAAGATTGGT <br />                                                                                      used PCR amplify 605-bp 5=-flanking DNA fragment L. <br />                                                                                      donovani cGAPDH gene primers 5=gacgggatccAGTCGCTATCGCTT <br />                                                                                      CTCAGC 5=gacgagatctACATCGATATGCAACGACGA the <br />                                                                                      584-bp 3=-flanking DNA fragment. The 605-bp 5=-flanking DNA frag- <br />                                                                                      ment digested HindIII BglII inserted HindIII and <br />                                                                                      BamH I sites pSPY-ble (35) pSPY-hyg (40) vector (upstream of <br />                                                                                      bleomycin phosphotransferase gene hygromycin phospho- <br />                                                                                      transferase gene); 584-bp 3=-flanking DNA fragment digested with <br />                                                                                      BamHI BglII ligated BglII site pSPY-ble or <br />                                                                                      pSPY-hyg vector (downstream bleomycin phosphotransferase gene <br />                                                                                      hygromycin phosphotransferase gene). The gene-targeting frag- <br />                                                                                      ment containing phleomycin hygromycin resistance gene flanked <br />                                                                                      5= 3= L. donovani cGAPDH gene-flanking sequences re- <br />                                                                                      leased targeting vectors HindIII BglII double digestion. <br />                                                                                      The targeting fragment DNA (5 8 &#226;?&#174;g) purified agarose gel was <br />                                                                                      used transfect L. donovani promastigotes primary secondary gene <br />                                                                                      targeting. For first-round gene targeting, L. donovani transfectants <br />                                                                                      selected culture medium containing 100 &#226;?&#174;g/ml hygromycin. For <br />                                                                                      second-round gene targeting, single L. donovani cGAPDH gene <br />                                                                                      knockouts transfected phleomycin targeting construct (20 <br />                                                                                      &#226;?&#174;g/ml phleomycin [Cayla]). <br />                                                                                          Measurement Leishmania proliferation vitro culture. The <br />                                                                                      growth curves Leishmania transfectants measured previously <br />                                                                                      described (33, 38, 39). Briefly, promastigotes stationary phase were <br />                                                                                      seeded concentration 2 &#226;&#171;&#187; 106 cells/ml 96-well plates containing <br />                                                                                      200 &#226;?&#174;l promastigote culture medium 27&#194;&#176;C, pH 7.4, vitro axenic <br /> FIG 1 Glycosomal cytosolic glycolytic pathway L. donovani. The gly-           amastigote culture medium 37&#194;&#176;C, pH 5.5. Each sample plated in <br /> colytic pathway glucose 3-phosphoglycerate (3-PGA) takes place           triplicate. The optical density 600 nm (OD600) values measured <br /> mainly glycosomes. In Leishmania species, L. donovani        directly plate daily 5 7 days. <br /> L. mexicana, sixth seventh steps pathway GAP 3-PGA            Glucose consumption assay. To compare glucose consumption of <br /> can occur cytosol, final steps lead formation     L. donovani wild-type cGAPDH-null mutant cells, log-phase promas- <br /> pyruvate cytosolic. G6P, glucose-6-phosphate; F6P, fructose-6-phos-         tigotes suspended fresh promastigote axenic amastigote culture <br /> phate; DHAP, dihydroxyacetone phosphate; 2-PGA, 2-phosphoglycerate. En-              medium containing 8 mM glucose cell density 1.5 &#226;&#171;&#187; 107/ml; 200-&#226;?&#174;l <br /> zymes: 1, hexokinase; 2, glucose-6-phosphate isomerase; 3, 6-phospho-1-fruc-         cultures taken culture 6 22 h, respectively; and <br /> tokinase; 4, fructose-1,6-bis-phosphate aldolase; 5, triosephosphate isomerase; 6, <br />                                                                                      Leishmania cells removed centrifugation. The glucose concentra- <br /> glyceraldehyde 3-phosphate dehydrogenase; 7, phosphoglycerate kinase; 8, phos- <br /> phoglycerate mutase; 9, enolase; 10, pyruvate kinase; 11, pentose phosphate path-    tion culture supernatants determined glucose assay kit <br /> way enzymes, including glucose 6-phosphate dehydrogenase, gluconolactonase,          according manufacturer&#226;&#8364;&#8482;s instructions (Eton Bioscience Inc.). <br /> 6-phosphogluconate dehydrogenase, ribulose 5-phosphate isomerase; 12,                Infection BALB/c mice. Female BALB/c mice infected tail <br /> transketolase.                                                                       vein injection 1 &#226;&#171;&#187; 108 stationary-phase promastigotes 100 &#226;?&#174;l PBS <br />                                                                                      mouse (33, 35, 36, 38, 39). Four weeks postinfection, amastigotes <br />                                                                                      isolated livers spleens infected mice. The recovered <br /> U/ml penicillin, 100-&#226;?&#174;g/ml streptomycin, 0.1 mM adenosine, 10 &#226;?&#174;g/ml                  amastigotes cultured promastigote culture medium, the <br /> folic acid, 25 mM HEPES, pH 7.4. The RPMI glucose medium                     Leishmania parasite burdens determined limiting dilution. The <br /> prepared adding glucose (1 g/liter) above-mentioned RPMI                   liver parasite burdens measured counting amastigotes in <br /> glucose-deficient medium.                                                            Giemsa-stained liver imprints, expressed Leishman-Donovan units <br />     Leishmania promastigotes routinely cultured 27&#194;&#176;C, pH 7.4,              (LDU), follows: number amastigotes 1,000 cell nuclei &#226;&#171;&#187; liver <br /> glucose-rich medium. To determine Leishmania proliferation dif-                weight (g) (35, 41). <br /> ferent culture conditions, Leishmania promastigotes shifted to <br /> glucose-deficient medium 37&#194;&#176;C, pH 5.5, culture medium (axenic <br />                                                                                      RESULTS <br /> amastigote medium) mimic macrophage phagolysosome environ- <br /> ment associated amastigote stage (37).                                      GAPDH gene distribution sequenced Trypanosoma and <br />     Construction Leishmania expression vectors. The L. donovani                   Leishmania species. Comparison trypanosomatid genomes in <br /> cGAPDH gene (an ortholog L. infantum cGAPDH gene,                             TriTrypDB (http://tritrypdb.org/tritrypdb) revealed se- <br /> LinJ.36.2480) PCR amplified L. donovani genomic DNA                     quenced Trypanosoma Leishmania species contain two <br /> with following primers: forward primer, 5=-cccaagcttaccATGGTCAA                  copies gGAPDH genes tandem array. One copy a <br /> AGTGGGCATCAAC, reverse primer 1, 5=-gacgagatcTCAGCGCGC                           cGAPDH-encoding gene present L. mexicana, L. <br /> GGACGTGTAGAGAA, reverse primer 2 (for fusion A2 tag),                     donovani complex species, Leishmania tarentolae, se- <br /> 5=-cgagatctgtGCGCGCGGACGTGTAGAGAA (lowercase letters repre-                          quenced Trypanosoma species. Surprisingly, cGAPDH gene, <br /> sent restriction sites added 5= end primer). The PCR <br />                                                                                      cytosolic phosphoglycerate kinase gene, ab- <br /> products double digested HindIII BglII cloned into <br /> pLPneo, pLGFPC, pLGFPN vectors (33, 34, 38, 39). pLGFPC                      sent L. braziliensis, cGAPDH gene pseu- <br /> used express green fluorescent protein (GFP) fusion proteins Leish-            dogene L. major (22, 23, 42). Interestingly, L. tarento- <br /> mania GFP N terminus; pLGFPN GFP C terminus.                  lae possesses cGAPDH gene, does cytosolic <br />     Constructs gene targeting. To make gene-targeting constructs             phosphoglycerate kinase gene. The L. infantum cGAPDH 80 to <br /> for L. donovani cGAPDH gene, primers 5=-gacccaagcttCTCACCTCT                     85% identity counterparts L. mexicana Trypano- <br />  <br />  <br /> January 2013 Volume 12 Number 1                                                                                                                   ec.asm.org 71 <br />  Zhang et al. <br />  <br />  <br />  <br />  <br /> FIG 2 Amino acid sequence alignments L. infantum cGAPDH (Lic) (LinJ.36.2480) L. mexicana cGAPDH (Lmxc) (LmxM.36.2350), L. major <br /> cGAPDH pseudogene product (Lmc) (LmjF.36.2350), L. infantum gGAPDH (Lig) (LinJ.30.3000). The dashes represent identical amino acids; dots <br /> represent amino acid gaps introduced better alignment. The stop codon amino acid 58 L. major cGAPDH pseudogene coding sequence marked <br /> with asterisk. The tripeptide AKM (boldface) glycosomal targeting signal present C terminus L. infantum gGAPDH. Note following data <br /> are shown: L. donovani BPK282A1 cGAPDH amino acid differences L. infantum cGAPDH (Ld:A287G:Li Ld:D302E:Li). <br />  <br />  <br />  <br /> soma species. As L. major genome sequence shows, PCR <br /> and sequencing analysis confirmed stop codon present at <br /> amino acid position 58 alleles cGAPDH gene L. <br /> major. Given available ATG translation initiation site <br /> is amino acid position 118, gene product will <br /> miss 117-amino-acid sequence, contains the <br /> NAD&#226;&#171;&#185; binding domain critical GAPDH function. Interest- <br /> ingly, L. major pseudogene 82% amino acid identity to <br /> L. infantum cGAPDH (Fig. 2). Since selective pressure <br /> to retain nonfunctional sequence, suggests the <br /> cGAPDH gene turned pseudogene recent evolution <br /> event L. major. L. infantum cGAPDH shares 55% identity <br /> with gGAPDH (Fig. 2). It important note recent rese- <br /> quencing L. major L. braziliensis genomes con- <br /> firmed cGAPDH gene pseudogene L. major is <br /> missing L. braziliensis (23). <br />     Initially, necessary confirm L. donovani <br /> cGAPDH present cytosol. Fusion proteins with <br /> GFP generated expressed transfected L. don- <br /> ovani. As shown Fig. 3, expression cGAPDH-GFP fusion <br /> proteins L. donovani (genetically closely related L. infan- <br /> tum) confirmed cGAPDH evenly distributed throughout <br /> the L. donovani promastigotes absent nucleus and <br /> kinetoplast, demonstrating enzyme confined                    FIG 3 Cytosolic localization L. donovani cGAPDH. (A) Western blot with <br /> glycosomes.                                                                      anti-GFP antibodies showing expression cGAPDH-GFP GFP-cGAPDH <br />     Generation L. donovani cGAPDH-null mutant. Since                       fusion protein transfected L. donovani promastigotes. (B) Cytosolic local- <br /> the glycolytic pathway largely occurs glycosomes cGAPDH                   ization cGAPDH-GFP GFP-cGAPDH fusion proteins L. donovani <br />                                                                                  promastigotes. Note L. donovani cGAPDH evenly distributed the <br /> is present Leishmania species, considerable                 cytosol present nucleus kinetoplast. The nuclear (N) and <br /> interest determine role cGAPDH enzyme L. don-                   kinetoplast (K) DNAs stained white 4=,6-diamidino-2-phenylindole <br /> ovani. To investigate this, undertook genetic approach                   (DAPI) fluorescent dye cells. The bars represent 2 &#226;?&#174;M. <br />  <br />  <br />  <br /> 72   ec.asm.org                                                                                                                                   Eukaryotic Cell <br />                                                                                                                                        L. donovani Cytosolic GAPDH <br />  <br />  <br />  <br />  <br /> FIG 4 Generation L. donovani cGAPDH-null mutant. (A) Homologous <br /> replacement strategy hygromycin bleomycin resistance gene-target- <br /> ing constructs. The black lines represent 5= 3= sequences flanking <br /> the cGAPDH gene. The primers used verify correct gene replacement <br /> events sizes PCR products indicated: F, forward primer; R, <br /> reverse primer; Hyg, hygromycin resistance gene-specific primer; Ble, bleomy- <br /> cin resistance gene-specific primer; E, primer downstream 3=- <br /> flanking targeting sequence. (B) PCR analysis wild-type L. donovani cells <br /> (&#226;&#171;&#185;/&#226;&#171;&#185;), single cGAPDH-targeting (hygromycin) cell line (&#226;&#171;&#185;/&#226;&#171;&#186;), double <br /> cGAPDH replacement cell line (null mutant; &#226;&#171;&#186;/&#226;&#171;&#186;), primer pairs indi-        FIG 5 In vitro proliferation curves L. donovani cGAPDH-null mutant in <br /> cated.                                                                             glucose-containing medium added pyruvate. (A) Promastig- <br />                                                                                    ote growth curves. (B) Axenic amastigote growth curves. LdWT, wild-type L. don- <br />                                                                                    ovani; cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186;, L. donovani cGAPDH-null mutant; cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186;&#226;&#171;&#185;, <br />                                                                                    cGAPDH-null mutant plus L. donovani cGAPDH episomal expression <br /> generating L. donovani cGAPDH-null mutant using gene tar-                       plasmid; cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186; (Pyru), cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186; mutant medium supple- <br /> geting. As shown Fig. 4, rounds gene targeting                      mented 1 mM pyruvate. The data means triplicate OD600 values &#226;&#171;&#190; <br />                                                                                    standard errors mean (SEM). The cell density differences the <br /> successfully carried delete alleles cGAPDH gene.                wild type cGAPDH-null mutant statistically significant starting <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> <br /> After round gene targeting hygromycin resis-                 day 2 promastigote axenic amastigote cultures (*, P &#226;&#172;? 0.05; **, P &#226;&#172;? <br /> tance gene-targeting construct, PCR analysis primer spe-                  0.01). The data representative independent experiments. <br /> cific hygromycin resistance gene (Hyg) primer <br /> (E) flanking sequence downstream 3=cGAPDH obtained <br /> a predicted 725-bp PCR fragment (Hyg &#226;&#171;&#185; E), demonstrating                      cells. The reduced proliferation cGAPDH-null mutant <br /> the Hyg resistance gene correctly targeted                       corrected supplementing medium pyru- <br /> cGAPDH gene alleles. Similarly, bleomycin resistance gene-tar-                   vate, suggesting growth defect result reduced <br /> geting construct used replacing second cGAPDH gene                     capacity synthesize pyruvate cell (see Discussion). <br /> allele. As shown Fig. 4B, predicted 834-bp PCR fragment                         To investigate reduced proliferation cGAPDH- <br /> (Ble &#226;&#171;&#185; E) obtained primer specific bleomycin                    null mutant resulted factors unrelated glycolysis, the <br /> resistance gene flanking primer E, demonstrating                      cGAPDH-null mutant wild-type cells cultured glu- <br /> bleomycin resistance gene correctly targeted remaining                  cose-deficient medium direct cells use energy <br /> cGAPDH gene allele. Thus, expected, cGAPDH gene PCR                          sources, fatty acid, proline, threonine, previously <br /> fragment present PCR analysis primer pairs (F                   described procyclic T. brucei (43). As expected, wild <br /> R) specific cGAPDH gene resulting L. donovani                       type cGAPDH-<span id='am-82' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-83' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-87' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-92' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-96' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-100' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-103' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-118' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-120' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-121' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-126' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-127' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-139' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-143' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-159' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span>null mutants</span> proliferated more <br /> mutant.                                                                            slowly glucose-deficient medium glucose-containing <br />     Proliferation L. donovani cGAPDH-null mutant                     medium (Fig. 6). However, despite lower proliferation rate, <br /> presence absence glucose. We initially compared pro-                    cGAPDH-null mutant able proliferate rate similar <br /> liferation wild type cGAPDH-null mutant axenic                   wild-type L. donovani cells glucose-deficient <br /> promastigotes amastigotes normal glucose-containing me-                     medium. This indicates cGAPDH required normal <br /> dia. As shown Fig. 5, null mutant displayed significant                   proliferation glucose-containing medium, suggesting that <br /> reduction proliferation compared control. Addition                    cGAPDH participates cytosolic glycolysis pathway pro- <br /> the cGAPDH gene episomal vector null mutant                      vide energy optimal proliferation. <br /> was able restore growth rate near level wild-type                 To investigate role cGAPDH glycolysis L. <br />  <br />  <br /> January 2013 Volume 12 Number 1                                                                                                                     ec.asm.org 73 <br />  Zhang et al. <br />  <br />  <br />  <br />  <br /> FIG 6 In vitro growth curves L. donovani cGAPDH-null mutant promasti- <br /> gotes medium glucose. LdWT, wild-type L. donovani; <br /> cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186;, cGAPDH-null mutant; &#226;&#171;&#185;Glu, medium 1 g/liter glucose; <br /> &#226;&#171;&#186;Glu, medium glucose. The data means triplicate OD600 <br /> values &#226;&#171;&#190; SEM. The cell density differences wild type the <br /> cGAPDH-null mutant statistically significant starting day 2 glu- <br /> cose-containing culture day 3 glucose-deficient culture (*, P &#226;&#172;? <br /> 0.05; **, P &#226;&#172;? 0.01). The data representative independent experi- <br /> ments. Note counted cells time point microscope; we <br /> found cell numbers good agreement OD600 values, <br /> although OD600 values appeared low glucose-deficient medium. <br />  <br />  <br />                                                                                   FIG 7 The L. donovani cGAPDH-null mutant consumes glucose than <br /> donovani, compared glucose consumption wild-type L.                     wild-type L. donovani culture medium containing glucose. Log-phase pro- <br /> donovani, cGAPDH-null mutant, cGAPDH add-back                         mastigotes suspended fresh promastigote axenic amastigote culture <br /> cells culture medium containing glucose. Equal numbers                      medium containing 8 mM glucose cell density 1.5 &#226;&#171;&#187; 107/ml. Glucose <br /> log-phase wild-type L. donovani cells cGAPDH mutants                      concentrations media culture 6 22 h determined. (A) <br />                                                                                   Glucose consumption promastigote culture. (B) Glucose consumption in <br /> were suspended fresh axenic promastigote amastigote cul-                    axenic amastigote culture. LdWT, wild-type L. donovani; cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186;, <br /> ture medium, glucose consumption determined mea-                       cGAPDH-null mutant; cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186;&#226;&#171;&#185;, cGAPDH-null mutant plus L. <br /> suring glucose concentrations culture medium 6                   donovani cGAPDH episomal expression plasmid. The data means of <br /> and 22 h. As shown Fig. 7, 6 h, glucose concentration                glucose concentrations triplicate cultures &#226;&#171;&#190; SEM. The glucose concentra- <br /> was slightly lower wild-type L. donovani cGAPDH add-                    tion differences culture media wild type cGAPDH-null <br />                                                                                   mutant statistically significant culture 22 h promastigote <br /> back cell cultures cGAPDH-null mutant culture. How-                       culture axenic amastigote culture (*, P &#226;&#172;? 0.05; **, P &#226;&#172;? 0.01). The data are <br /> ever, significant difference glucose concentration                  representative independent experiments. <br /> was observed culture 22 h. The cGAPDH-null mutant <br /> utilizes glucose wild-type cGAPDH add-back cells in <br /> both promastigote axenic amastigote culture, strongly sug-                    placed glucose-containing glucose-deficient medium. Inter- <br /> gesting cGAPDH involved glycolysis L. donovani.                     estingly, glucose-containing medium, presence cGAPDH <br />     The L. donovani cGAPDH-null mutant displays reduced in-                       suppressed L. major proliferation reduced cell density sta- <br /> fectivity visceral organs. To examine L. donovani re-                  tionary phase compared control (Fig. 9). In contrast, the <br /> quires cGAPDH survival visceral organs, BALB/c mice                   proliferation L. major containing cGAPDH similar that <br /> infected wild-type cGAPDH-null mutant promastigotes                      control glucose-deficient medium. This indicates that, <br /> by intravenous injection, infection levels determined                unlike L. donovani, cGAPDH activity beneficial may <br /> after 4 weeks. As shown Fig. 8, liver spleen parasite                  harmful L. major. cGAPDH-containing L. major consumed <br /> burdens mice infected cGAPDH-null mutant                         glucose control transfected L. major glucose- <br /> significantly reduced compared wild-type L. donovani-in-                     containing culture medium, adverse <br /> fected mice. Addition cGAPDH gene episomal vector                    effect cGAPDH L. major (data shown). <br /> back null mutant able partially restore infectivity, <br /> confirming requirement cGAPDH visceral organ sur-                      DISCUSSION <br /> vival.                                                                            Since glycolytic pathway glucose 3-phosphoglycerate <br />     Restoration cGAPDH activity suppressed L. major prolif-                    place exclusively glycosomes, clear the <br /> eration glucose-containing, glucose-deficient, me-                     cytosolic counterpart GAPDH present Leishma- <br /> dium. Unlike L. donovani, cGAPDH gene                         nia species, L. donovani. In study, demonstrate that <br /> pseudogene L. major (Fig. 2). It interesting                  deletion L. donovani cGAPDH gene reduced glucose uptake, <br /> investigate restoring cGAPDH activity L. major                   suppressed proliferation glucose-containing medium, and, <br /> result increased proliferation presence glucose. An                  significantly, attenuated survival visceral organs. These <br /> episomal expression vector containing L. donovani cGAPDH                      observations indicate cGAPDH gene L. donovani is <br /> gene transfected L. major, transfectants                    functional plays role visceral disease pathogenesis. <br />  <br />  <br /> 74   ec.asm.org                                                                                                                                    Eukaryotic Cell <br />                                                                                                                                       L. donovani Cytosolic GAPDH <br />  <br />  <br />  <br />  <br />                                                                                 FIG 9 In vitro promastigote proliferation curves L. major containing L. <br />                                                                                 donovani cGAPDH gene (Lm&#226;&#171;&#185;cGAPDH) control transfected L. major (Lm <br />                                                                                 neo) medium (&#226;&#171;&#185;Glu) (&#226;&#171;&#186;Glu) glucose. The data means <br />                                                                                 triplicates &#226;&#171;&#190; SEM. The cell density differences Lm&#226;&#171;&#185;cGAPDH Lm <br />                                                                                 neo statistically significant starting day 3 glucose-containing culture <br />                                                                                 (*, P &#226;&#172;? 0.05; **, P &#226;&#172;? 0.01). The data representative independent exper- <br /> FIG 8 The L. donovani cGAPDH-null mutant displayed reduced infectivity       iments. <br /> the livers spleens BALB/c mice. L. donovani cGAPDH mutants were <br /> used infect BALB/c mice tail vein injection (5 mice group); 4 weeks <br /> after infection, mice examined liver spleen parasite burden. <br /> (A) Liver parasite burden. (B) Spleen parasite burden. LdWT, wild-type L.       phosphoenolpyruvate (PEP) generated glycolysis enters the <br /> donovani; cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186;, cGAPDH-null mutant; cGAPDH&#226;&#171;&#186;/&#226;&#171;&#186;&#226;&#171;&#185;, cGAPDH-                    glycosome fermented succinate regenerate ATP <br /> null mutant plus L. donovani cGAPDH episomal expression plasmid. The        NAD&#226;&#171;&#185; consumed upper glycolytic pathway reactions, and <br /> data means plus SEM. The LDU spleen parasite burden differences <br /> are statistically significant (P &#226;&#172;? 0.01) mice infected         C4 dicarboxylic acids generated succinate fer- <br /> cGAPDH-null mutant mice infected wild-type parasites            mentation catabolized tricarboxylic acid (TCA) <br /> cGAPDH add-back mutant. The experiment repeated times sim-         cycle (32). This explain cGAPDH-null mutant pro- <br /> ilar results.                                                                   liferation rate improved supplementing medium <br />                                                                                 pyruvate, shown Fig. 5. <br />                                                                                     It suggested proteomic analysis dif- <br />     It previously observed glycolytic intermediates               ferentiation extracellular promastigotes intracellular <br /> can equilibrate glycosome membranes cytosol                 amastigotes, Leishmania parasites shift glucose amino ac- <br /> (28). Indeed, recent study suggested glycosome mem-                   ids fatty acids main energy sources (45). However, <br /> brane contains types pore-forming channels allow                studies shown glucose and/or amino sugars are <br /> movement small solutes membrane, including inter-                 required amastigote stage, mainly <br /> mediate metabolites glycolysis molecular masses 300               needed formation glycoconjugates (46&#226;&#8364;&#8220;49). Leishmania <br /> to 400 Da (27). Together observations study,               amastigotes able utilize amino sugars phagolysosome <br /> parallel glycolytic pathway beginning sixth step glycol-            mammalian macrophages source carbon energy <br /> ysis place cytosol Leishmania species            (47). Interestingly, gene deletion study gluconeogenic en- <br /> expressing cGAPDH (Fig. 1). Since silico analysis glycolytic              zyme fructose-1,6-bisphosphatase (FBP) showed Leishmania also <br /> flux bloodstream form T. brucei shows GAPDH                    requires gluconeogenesis virulence (50). Since GAPDH is <br /> enzymes play role control glycolytic                 able catalyze reverse reaction 3-phospho-D-glyc- <br /> pathway (9&#226;&#8364;&#8220;11), presence partial parallel glycolytic                 eroyl phosphate GAP gluconeogenesis. The observation in <br /> pathway L. donovani cytosol increase overall gly-              study L. donovani cGAPDH-null mutant reduced <br /> colytic flux generation ATP. The partial parallel               infectivity visceral organs suggests cGAPDH in- <br /> glycolytic pathway help balance cytosolic NAD&#226;&#171;&#185;/                 volved glycolysis and/or gluconeogenesis pathways L. <br /> NADH ratio. Throughout study, observed growth                   donovani resides amastigote macrophage phagolyso- <br /> the L. donovani cGAPDH-null mutants appeared pro-                    some, sugar levels relatively low (47, 51). <br /> foundly affected late log stationary phases                  The available crystal structures T. brucei, T. cruzi, L. <br /> early log phase (Fig. 5 6). This fact          mexicana gGAPDHs enabled design inhibitors that <br /> fast-growing Leishmania cells log phase require active                  effectively block trypanosomatid gGAPDH, lethal <br /> glycolytic flux GAPDH activity energy production (11,                   bloodstream T. brucei intracellular T. cruzi (10, 15&#226;&#8364;&#8220;17). The <br /> 44), accumulating effect makes cell density difference              bloodstream stage T. brucei uses glycolysis energy <br /> more obvious late log stationary phases early log                source cytosolic phosphoglycerate kinase expression is <br /> phase.                                                                          suppressed, explain inhibitors gGAPDH are <br />     A recent glucose metabolic labeling study L. mexicana pro-               lethal bloodstream T. brucei. However, unknown whether <br /> mastigotes shown that, instead converted pyru-                gGAPDH inhibitors inhibit cGAPDH and <br /> vate, usual final product aerobic glycolysis, majority            lethal L. mexicana (10). Together the <br />  <br />  <br /> January 2013 Volume 12 Number 1                                                                                                                    ec.asm.org 75 <br />  Zhang et al. <br />  <br />  <br />  <br /> observations study, appropriate develop                       submicromolar, biologically active inhibitors trypanosomatid glyceral- <br /> inhibitors cGAPDH L. donovani, null mutant                       dehyde-3-phosphate dehydrogenase. Proc. Natl. Acad. Sci. U. S. A. 96: <br />                                                                                      4273&#226;&#8364;&#8220; 4278. <br /> significantly attenuated visceral organs. However, ideal in-            11.   ter Kuile BH. 1999. Regulation adaptation glucose metabolism of <br /> hibitor capable blocking glycosomal                        parasitic protist Leishmania donovani enzyme mRNA levels. <br /> cytosolic GAPDH activities. This difficult single                      J. Bacteriol. 181:4863&#226;&#8364;&#8220; 4872. <br /> inhibitor, enzymes share 55% homology.                          12.   Kim H, Feil IK, Verlinde CL, Petra PH, Hol WG. 1995. Crystal structure <br />     It clear cGAPDH gene evolved pseu-                     glycosomal glyceraldehyde-3-phosphate dehydrogenase Leishma- <br />                                                                                      nia mexicana: implications structure-based drug design new <br /> dogene L. major absent L. braziliensis present L.                position inorganic phosphate binding site. Biochemistry 34: <br /> donovani L. mexicana. Unlike Leishmania species, L.                        14975&#226;&#8364;&#8220;14986. <br /> braziliensis does cytosolic phosphoglycerate kinase              13.   Souza DH, Garratt RC, Ara&#195;&#186;jo AP, Guimar&#195;&#163;es BG, Jesus WD, Michels <br /> (cPGK). In present study, expected introduc-                     PA, Hannaert V, Oliva G. 1998. Trypanosoma cruzi glycosomal glycer- <br />                                                                                      aldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism <br /> tion L. donovani cGAPDH L. major result an <br />                                                                                      targeted inhibitor design. FEBS Lett. 424:131&#226;&#8364;&#8220;135. <br /> adverse effect proliferation glucose-containing medium.                  14.   Vellieux FM, Hajdu J, Hol WG. 1995. Refined 3.2 A structure glyco- <br /> This provide rationale gene evolved                     somal holo glyceraldehyde phosphate dehydrogenase Trypanosoma <br /> into pseudogene L. major.                                                       brucei brucei. Acta Crystallogr. D Biol. Crystallogr. 51:575&#226;&#8364;&#8220;589. <br />     The principal function GAPDH catalyze sixth step              15.   Callens M, Hannaert V. 1995. The rational design trypanocidal drugs: <br />                                                                                      selective inhibition glyceraldehyde-3-phosphate dehydrogenase in <br /> of glycolysis produce energy carbon molecules. In addition,                   Trypanosomatidae. Ann. Trop. Med. Parasitol. 89(Suppl. 1):23&#226;&#8364;&#8220;30. <br /> GAPDH recently implicated nonmetabolic                     16.   Suresh S, Bressi JC, Kennedy KJ, Verlinde CL, Gelb MH, Hol WG. <br /> processes higher eukaryotic cells, including transcription acti-                  2001. Conformational changes Leishmania mexicana glyceraldehyde- <br /> vation, initiation apoptosis, endoplasmic reticulum (ER)-                     3-phosphate dehydrogenase induced designed inhibitors. J. Mol. Biol. <br /> to-Golgi apparatus vesicle shuttling (52, 53). An indication                      309:423&#226;&#8364;&#8220; 435. <br />                                                                                17.   Verlinde CL, Hannaert V, Blonski C, Willson M, P&#195;&#169;ri&#195;&#169; JJ, Fothergill- <br /> GAPDH involvement nonmetabolic processes higher eu-                            Gilmore LA, Opperdoes FR, Gelb MH, Hol WG, Michels PA. 2001. <br /> karyotic cells translocation enzyme nucleus                  Glycolysis target design new anti-trypanosome drugs. Drug <br /> response cellular stress (53). Our studies showed                  Resist. Updat. 4:50 &#226;&#8364;&#8220; 65. <br /> no translocation nucleus L. donovani GFP-cGAPDH                   18.   Hannaert V, Blaauw M, Kohl L, Allert S, Opperdoes FR, Michels PA. <br />                                                                                      1992. Molecular analysis cytosolic glycosomal glyceraldehyde- <br /> fusion proteins (Fig. 3) Leishmania cells exposed                    3-phosphate dehydrogenase Leishmania mexicana. Mol. Biochem. <br /> to cellular stress, serum withdrawal stress induced                    Parasitol. 55:115&#226;&#8364;&#8220;126. <br /> exposure hydrogen peroxide (data shown). It neverthe-                19.   Lambeir A-M, Loiseau AM, Kuntz DA, Vellieux FM, Michels PAM, <br /> less possible rule possibility L. donovani                       Opperdoes FR. 1991. The cytosolic glycosomal glyceraldedehyde-3- <br /> cGAPDH plays roles independent glycolysis.                                   phosphate dehydrogenase Trypanosoma brucei: kinetic properties <br />                                                                                      comparison homologous enzymes. Eur. J. Biochem. 198:429 &#226;&#8364;&#8220; <br />                                                                                      435. <br /> ACKNOWLEDGMENTS                                                                20.   Misset O, Van Beeumen J, Lambeir Van der Meer A-MR, Opperdoes <br /> This study supported operating grant Canadian Insti-              FR. 1987. Glyceraldehydephosphate dehydrogenase Trypanosoma <br /> tute Health Research (CIHR). L.-I.M. acknowledges receiving                brucei. Comparison glycosomal cytosolic isoenzymes. Eur. J. <br />                                                                                      Biochem. 162:501&#226;&#8364;&#8220;507. <br /> graduate scholarship CIHR. <br />                                                                                21.   Michels PA, Poliszczak A, Osinga KA, Misset O, Van Beeumen J, <br />                                                                                      Wierenga RK, Borst P, Opperdoes FR. 1986. Two tandemly linked <br /> REFERENCES                                                                           identical genes <span id='am-2' about='Thesaurus:code' typeof='owl:Thing'>code</span> glycosomal glyceraldehyde-phosphate dehy- <br />  1. Gualdr&#195;&#179;n-L&#195;&#179;pez M, Brennand A, Hannaert V, Qui&#195;&#177;ones W, C&#195;&#161;ceres                    drogenase Trypanosoma brucei. EMBO J. 5:1049 &#226;&#8364;&#8220;1056. <br />     AJ, Bringaud F, Concepci&#195;&#179;n JL, Michels PA. 2012. When,         22.   Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, Peters <br />     glycolysis compartmentalised Kinetoplastea. A new look          N, Adlem E, Tivey A, Aslett M, Kerhornou A, Ivens A, Fraser A, <br />     ancient organelle. Int. J. Parasitol. 42:1&#226;&#8364;&#8220;20.                                Rajandream MA, Carver T, Norbertczak H, Chillingworth T, Hance Z, <br />  2. Hannaert V, Bringaud F, Opperdoes FR, Michels PAM. 2003. Evolution               Jagels K, Moule S, Ormond D, Rutter S, Squares R, Whitehead <br />     energy metabolism compartmentation Kinetoplastida. Ki-             S, Rabbinowitsch E, Arrowsmith C, White B, Thurston S, Bringaud F, <br />     netoplastid Biol. Dis. 2:11.                                                     Baldauf SL, Faulconbridge A, Jeffares D, Depledge DP, Oyola SO, <br />  3. Hannaert V, Michels PAM. 1994. Structure, function, biogenesis            Hilley JD, Brito LO, Tosi LR, Barrell B, Cruz AK, Mottram JC, Smith <br />     glycosomes Kinetoplastida. J. Bioenerg. Biomembr. 26:205&#226;&#8364;&#8220;212.                 DF, Berriman M. 2007. Comparative genomic analysis Leishma- <br />  4. Michels PA, Bringaud F, Herman M, Hannaert V. 2006. Metabolic                    nia species cause diverse human disease. Nat. Genet. 39:839 &#226;&#8364;&#8220; 847. <br />     functions glycosomes trypanosomatids. Biochim. Biophys. Acta         23.   Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, Depledge DP, <br />     1763:1463&#226;&#8364;&#8220;1477.                                                                  Harris D, Her Y, Herzyk P, Imamura H, Otto TD, Sanders M, Seeger <br />  5. Michels PA, Hannaert V, Bringaud F. 2000. Metabolic aspects glyco-            K, Dujardin JC, Berriman M, Smith DF, Hertz-Fowler C, Mottram JC. <br />     somes Trypanosomatidae&#226;&#8364;&#8221;new data views. Parasitol. Today 16:               2011. Chromosome gene copy number variation allow major struc- <br />     482&#226;&#8364;&#8220; 489.                                                                        tural change species strains Leishmania. Genome Res. <br />  6. Opperdoes FR. 1987. Compartmentation carbohydrate metabolism               21:2129 &#226;&#8364;&#8220;2142. <br />     trypanosomes. Annu. Rev. Microbiol. 41:127&#226;&#8364;&#8220;151.                            24.   Michels PA, Marchand M, Kohl L, Allert S, Wierenga RK, Opperdoes <br />  7. Opperdoes FR, Borst P. 1977. Localization glycolytic enzymes          FR. 1991. The cytosolic glycosomal isoenzymes glyceraldehyde-3- <br />     microbody-like organelle Trypanosoma brucei: glycosome. FEBS            phosphate dehydrogenase Trypanosoma brucei distant evolu- <br />     Lett. 80:360 &#226;&#8364;&#8220;364.                                                               tionary relationship. Eur. J. Biochem. 198:421&#226;&#8364;&#8220; 428. <br />  8. Parsons M. 2004. Glycosomes: parasites divergence peroxi-       25.   Lake JA, la Cruz V, Ferreira PCG, Morel C, Simpson L. 1988. <br />     somal purpose, Mol. Microbiol. 53:717&#226;&#8364;&#8220;724.                                       Evolution parasitism: kinetoplastid protozoan history reconstructed <br />  9. Albert MA, Haanstra JR, Hannaert V, Van Roy J, Opperdoes FR,                     mitochondrial rRNA gene sequences. Proc. Natl. Acad. Sci. U. S. A. <br />     Bakker BM, Michels PA. 2005. Experimental silico analyses              85:4779 &#226;&#8364;&#8220; 4783. <br />     glycolytic flux control bloodstream form Trypanosoma brucei. J. Biol.   26.   Wiemer EA, Hannaert V, van den IJssel PR, Van Roy J, Opperdoes FR, <br />     Chem. 280:28306 &#226;&#8364;&#8220;28315.                                                          Michels PA. 1995. Molecular analysis glyceraldehyde-3-phosphate de- <br /> 10. Aronov AM, Suresh S, Buckner FS, Van Voorhis WC, Verlinde CL,                    hydrogenase Trypanoplasma borelli: evolutionary scenario sub- <br />     Opperdoes FR, Hol WG, Gelb MH. 1999. Structure-based design                   cellular compartmentation kinetoplastida. J. Mol. Evol. 40:443&#226;&#8364;&#8220; 454. <br />  <br />  <br />  <br /> 76   ec.asm.org                                                                                                                                 Eukaryotic Cell <br />                                                                                                                                        L. donovani Cytosolic GAPDH <br />  <br />  <br />  <br /> 27. Gualdron-Lopez M, Vapola MH, Miinalainen IJ, Hiltunen JK, Michels                   bacterial DNA plasmid oligomers Leishmania. Mol. Biochem. Parasitol. <br />     PAM, Antonenkov VD. 2012. Channel-forming activities glyco-                  65:39 &#226;&#8364;&#8220; 49. <br />     somal fraction bloodstream form Trypanosoma brucei. PLoS          41.   Zhang WW, Mendez S, Ghosh A, Myler P, Ivens A, Clos J, Sacks DL, <br />     One 7:e34530. doi:10.1371/journal.pone.0034530.                                     Matlashewski G. 2003. Comparison A2 gene locus Leishmania <br /> 28. Visser N, Opperdoes FR, Borst P. 1981. Subcellular compartmentation                 donovani Leishmania major control cutaneous infection. <br />     glycolytic intermediates Trypanosoma brucei. Eur. J. Biochem. 118:            J. Biol. Chem. 278:35508 &#226;&#8364;&#8220;35515. <br />     521&#226;&#8364;&#8220;526.                                                                      42.   Raymond F, Boisvert S, Roy G, Ritt JF, L&#195;&#169;gar&#195;&#169; D, Isnard A, Stanke M, <br /> 29. Kaur PK, Dinesh N, Soumya N, Babu NK, Singh S. 2012. Identification                 Olivier M, Tremblay MJ, Papadopoulou B, Ouellette M, Corbeil J. <br />     characterization novel ribose 5-phosphate isomerase B                 2012. Genome sequencing lizard parasite Leishmania tarentolae <br />     Leishmania donovani. Biochem. Biophys. Res. Commun. 421:51&#226;&#8364;&#8220;56.                      reveals loss genes associated intracellular stage human patho- <br /> 30. Maugeri DA, Cazzulo JJ, Burchmore RJ, Barrett MP, Ogbunude PO.                      genic species. Nucleic Acids Res. 40:1131&#226;&#8364;&#8220;1147. <br />     2003. Pentose phosphate metabolism Leishmania mexicana. Mol.               43.   Lamour N, Rivi&#195;&#168;re L, Coustou V, Coombs GH, Barrett MP, Bringaud <br />     Biochem. Parasitol. 130:117&#226;&#8364;&#8220;125.                                                    F. 2005. Proline metabolism procyclic Trypanosoma brucei down- <br /> 31. Blattner J, Helfert S, Michels P, Clayton C. 1998. Compartmentation              regulated presence glucose. J. Biol. Chem. 280:11902&#226;&#8364;&#8220;11910. <br />     phosphoglycerate kinase Trypanosoma brucei plays critical role        44.   Mukkada AJ, Schaefer FW, III, Simon MW, Neu C. 1974. Delayed in <br />     parasite energy metabolism. Proc. Natl. Acad. Sci. U. S. A. 95:11596 &#226;&#8364;&#8220;              vitro utilization glucose Leishmania tropica promastigotes. J. Proto- <br />     11600.                                                                              zool. 21:393&#226;&#8364;&#8220;397. <br /> 32. Saunders EC, Ng WW, Chambers JM, Ng M, Naderer T, Kr&#195;&#182;mer JO,                  45.   Rosenzweig D, Smith D, Opperdoes F, Stern S, Olafson RW, Zilberstein <br />     Likic VA, McConville MJ. 2011. Isotopomer profiling Leishmania                   D. 2008. Retooling Leishmania metabolism: sand fly gut human <br />     mexicana promastigotes reveals important roles succinate fermenta-              macrophage. FASEB J. 22:590 &#226;&#8364;&#8220; 602. <br />     tion aspartate uptake tricarboxylic acid cycle (TCA) anaplerosis,      46.   Burchmore RJ, Rodriguez-Contreras D, McBride K, Merkel P, Barrett <br />     glutamate synthesis, growth. J. Biol. Chem. 286:27706 &#226;&#8364;&#8220;27717.                   MP, Modi G, Sacks D, Landfear SM. 2003. Genetic characterization of <br /> 33. Zhang WW, Chan KF, Song Z, Matlashewski G. 2011. Expression                    glucose transporter function Leishmania mexicana. Proc. Natl. Acad. <br />     Leishmania donovani nucleotide sugar transporter Leishmania major                Sci. U. S. A. 100:3901&#226;&#8364;&#8220;3906. <br />     enhances survival visceral organs. Exp. Parasitol. 129:337&#226;&#8364;&#8220;345.            47.   Naderer T, Heng J, McConville MJ. 2010. Evidence intracellular <br /> 34. Zhang WW, Charest H, Matlashewski G. 1995. The expression bio-                   stages Leishmania major utilize amino sugars major carbon source. <br />     logically active human p53 Leishmania cells: novel eukaryotic           PLoS Pathog. 6:e1001245. doi:10.1371/journal.ppat.1001245. <br />     produce recombinant proteins. Nucleic Acids Res. 23:4073&#226;&#8364;&#8220; 4080.            48.   Rodriguez-Contreras D, Feng  <br /> </body></html>